MYC Genetic Alteration Cell Line Panel Item ID: ATCTCP1035
| Permits and Restrictions |
View Permits |
|---|---|
| Organism | Homo sapiens, human |
| Components | ATCC CRL-1647 ST486ATCC CRL-1648 CA46ATCC HTB-62 P3HR-1ATCC CRL-5974 SNU-16ATCC HTB-175 NCI-H82ATCC CRL-2081 MSTO-211HATCC HTB-171 NCI-H446ATCC CCL-240 HL-60ATCC CRL-9068 NCI-H929 |
| Applications | This validated panel is composed of 9 select human tumor cell lines carrying c-myc mutations or various degrees of c-myc gene copy number changes, and is useful for MYC pathway research and for anti-cancer drug discovery. |
| Biosafety Level |
2 [Cells contain Herpesvirus (EBV)]
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Comments | MYC is an oncogenic transcription factor which is encoded by the c-myc proto-oncogene. By regulating target gene expressions, MYC has diverse roles involved in cell growth, proliferation, biogenesis, cellular metabolism and apoptosis. Mutations or overexpression of c-myc gene has been detected in a wide range of human cancers, especially in lymphomas. The MYC genetic alteration cell panel (ATCC TCP-1035) is composed of nine selected human tumor cells that carry c-myc mutations or various degrees of c-myc gene copy number changes. The MYC status of each cell line has been sequenced and validated by ATCC. This panel is useful for studying MYC and its cellular effects on subsequent target genes and pathways in providing a platform for basic research and anti-cancer drug discovery. |
| Product Format | 9 cryopreserved cell lines |
| Storage Conditions | liquid nitrogen vapor phase (less than -130°C) only |
| Permits |
These permits may be required for shipping this product to Australia:
|
|---|---|
| Basic Documentation | Product Sheet Certificate of Analysis SDS |
| Other Documentation | Recommended Culture Conditions Genetic Alteration Panels - Brochure |